| AiTan (rivoceranib) / HLB Bio Group |
NCT03163381: Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study. |
|
|
| Unknown status | 2 | 40 | RoW | Apatinib | Henan Cancer Hospital, Jiangsu HengRui Medicine Co., Ltd. | Osteosarcoma, Advanced | 10/17 | 04/19 | | |
ChiCTR-OIC-17013792: A Single arm, open, prospective study of Mesylate apatinib in the treatment of advanced bone and soft tissue sarcoma |
|
|
| Recruiting | 2 | 20 | | Apatinib | Beijing Jishuitan Hospital; Beijing Jishuitan Hospital, Optional subject | Bone and soft tissue sarcoma | | | | |
| Unknown status | 2 | 53 | NA | apatinib, apatinib mesylate tablets | Shanghai Jiao Tong University Affiliated Sixth People's Hospital | Soft Tissue Sarcoma | 03/18 | 09/18 | | |
NCT03121846: Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy |
|
|
| Unknown status | 2 | 80 | RoW | Apatinib, Apatinib Mesylate Tablets | Tianjin Medical University Cancer Institute and Hospital, Zhejiang Cancer Hospital, Gansu Cancer Hospital, Liaoning Tumor Hospital & Institute, Fudan University | Soft Tissue Sarcoma, Adult, Stage II | 11/18 | 05/19 | | |
NCT03104335: Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial |
|
|
| Withdrawn | 2 | 0 | RoW | Apatinib, apatinib mesylate tablets | Peking University People's Hospital, Peking University Shougang Hospital, Peking University International Hospital | Soft Tissue Sarcoma Adult, Advanced Cancer | 06/19 | 03/20 | | |
| Completed | 2 | 43 | RoW | Apatinib, SHR-1210 | Peking University People's Hospital, Jiangsu HengRui Medicine Co., Ltd. | Progression-free Survival, Overall Survival, Clinical Benefit Rate, Toxicity | 10/19 | 01/20 | | |
RASS, NCT03539172: Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck-- Study |
|
|
| Unknown status | 2 | 61 | RoW | Apatinib Mesylate | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Soft Tissue and Bone Tumor, Head and Neck Cancer, Sarcoma | 12/19 | 03/20 | | |
NCT04126993: Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma |
|
|
| Unknown status | 2 | 80 | RoW | Camrelizumab,, Apatinib | Tianjin Medical University Cancer Institute and Hospital | Sarcoma | 12/19 | 12/20 | | |
NCT04126811: Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma |
|
|
| Unknown status | 2 | 120 | RoW | Apatinib Mesylate, Pirarubicin, Ifosfamide, Apatinib Mesylate, Pirarubicin, Ifosfamide | Tianjin Medical University Cancer Institute and Hospital | Soft Tissue Sarcoma | 12/19 | 12/20 | | |
ChiCTR-OIC-17011964: The prospective, open-lable, single-arm, single-center clinical study of Apatinib mesylate non-first-line used in treating patients with recurrent/metastatic soft tissue sarcoma. |
|
|
| Not yet recruiting | 2 | 25 | | Continuous administration of apatinib 500mg/ days | The Affiliated Tumor Hospital of Guangxi Medical University; The Affiliated Tumor Hospital of Guangxi Medical University, Self-raised | recurrent/metastatic soft tissue sarcoma | | | | |
ChiCTR1800020407: Efficacy and safety of apapitatin mesylate in the treatment of metastatic gastrointestinal stromal tumor (GIST) with failed imatinib mesylate or sunitinib |
|
|
| Recruiting | 2 | 30 | | Apatinib 500mg qd | West China Hospital, Sichuan University; West China Hospital, Sichuan University, CSCO Funding | Gastrointestinal stromal tumor | | | | |
NCT03711279: A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma |
|
|
| Terminated | 2 | 99 | RoW | SHR-1210 plus Apatinib, PD-1 antibody + Anti-angiogenesis, ADM plus IFO or IFO alone, chemotherapy | Jiangsu HengRui Medicine Co., Ltd. | Sarcoma | 06/21 | 06/21 | | |
NCT04447274: A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS |
|
|
| Unknown status | 2 | 20 | NA | Camrelizumab and Apatinib | Chinese Academy of Medical Sciences | Sarcoma | 12/21 | 12/21 | | |
NCT04239443: Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer |
|
|
| Unknown status | 2 | 120 | RoW | PD-1 inhibitor, Camrelizumab, Apatinib | Hunan Cancer Hospital, Jiangsu HengRui Medicine Co., Ltd. | Advanced Non Small Cell Lung Cancer, Uterine Cancer, Soft Tissue Sarcoma | 03/22 | 03/22 | | |
MAPAC, NCT04351308: Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma |
|
|
| Recruiting | 2 | 60 | RoW | MAPI chemotherapy, Apatinib Mesylate, Camrelizumab | Peking University People's Hospital, Chinese Sarcoma Study Group | Osteosarcoma, Survival, Chemotherapy Effect, Toxicity, Drug | 09/22 | 12/22 | | |
NCT05265793: Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma |
|
|
| Recruiting | 2 | 45 | RoW | Camrelizumab Combined With Apatinib, PD-1 immunotherapy and VEGFR-TKIs | Fudan University | PD-1 Immunotherapy, VEGFR-TKI, Sarcomatoid Carcinoma, Carcinosarcoma | 03/23 | 06/23 | | |
AIEO, NCT04824352: Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma |
|
|
| Suspended | 2 | 44 | RoW | apatinib, IE chemotherapy | Peking University People's Hospital, Peking University Shougang Hospital | Effect of Drug, Toxicity, Drug | 04/26 | 04/26 | | |
ChiCTR2000032649: A multicenter, open, single-arm, phase II study to evaluate the efficacy and safety of camrelizumab alone or in combination with Apatinib mesylate in patients with PD-L1-positive advanced lung sarcomatoid carcinoma |
|
|
| Not yet recruiting | 2 | 30 | | camrelizumab alone or in combination with Apatinib mesylate | The First Affiliated Hospital of China Medical University; The First Affiliated Hospital of China Medical University, Jiangsu Hengrui Pharmaceutical Co., Ltd | lung sarcomatoid carcinoma | | | | |
NCT04012827: Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma |
|
|
| Recruiting | 2 | 108 | RoW | Apatinib Mesylate, doxorubicin, ifosfamide, Apatinib | Sun Yat-sen University, Jiangsu HengRui Medicine Co., Ltd. | Soft Tissue Sarcoma | 06/23 | 12/23 | | |
OAIE, NCT05277480: Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma |
|
|
| Completed | 2 | 81 | RoW | Apatinib+IE, IE | Peking University People's Hospital, Jiangsu HengRui Medicine Co., Ltd. | Effect of Drug, Drug, Toxicity | 06/23 | 11/23 | | |
PROACH, NCT03742193: Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy |
|
|
| Active, not recruiting | 2 | 43 | RoW | Apatinib, VEGFR Inhibitor, GD regimen, Chemotherapy | Ruijin Hospital | Osteosarcoma, Pulmonary Metastases, Apatinib | 11/23 | 12/23 | | |
| Recruiting | 2 | 30 | RoW | Apatinib monotherapy, VEGFR inhibitor; Rivoceranib | Ruijin Hospital | Sarcoma | 10/26 | 09/27 | | |
ChiCTR2200062550: Phase II clinical study of apatinib tablet combined with chemotherapy in neoadjuvant therapy of adult osteosarcoma |
|
|
| Not yet recruiting | 2 | 24 | | Apatinib mesylate tablets combined with chemotherapy | Department of Orthopedics Oncology, Shanghai Changzheng Hospital; Shanghai Changzheng Hospital, Special funds | Osteosarcoma | | | | |
NCT05235100: Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma |
|
|
| Recruiting | 2 | 30 | RoW | Apatinib Mesylate | Chinese Academy of Medical Sciences | Sarcoma,Soft Tissue, Extremity, Trunk, Intensity-modulated Radiotherapy, Targetd Therapy, Major Wound Complications | 08/24 | 12/24 | | |
NCT06125171: Tucidinostat Plus Apatinib for Advanced Osteosarcoma |
|
|
| Not yet recruiting | 2 | 46 | NA | Tucidinostat, Apatinib | Wuhan Union Hospital, China | Osteosarcoma | 12/24 | 12/25 | | |
NCT05905887: Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor |
|
|
| Recruiting | 2 | 48 | RoW | Rivoceranib Mesylate, Paclitaxel | Asan Medical Center | Gastrointestinal Stromal Tumors | 08/26 | 12/26 | | |
ChiCTR2400086577: The efficacy and safety study of adebrelimab in combination with chemotherapy and apatinib for perioperative treatment of lung sarcomatoid carcinoma |
|
|
| Recruiting | 2 | 25 | | Pre-surgical neoadjuvant therapy phase1.Adebrelimab: 1200 mg IV, D1, Q3W, treatment for 2-4 cycles; 2. Apatinib: 250 mg, QD, half hour after meal, treatment for 2-4 cycles; 3. albumin paclitaxel: 260 mg/m2, D1, Q3W; 4. cisplatin: 70 mg/m2, D1, Q3W (no more than 130 mg)/carboplatin: 300-400 mg/m2, D1, Q3W.Chemotherapy may be given in split doses before and after surgery for a total of no more than 4 cycles of treatment.Surgery was performed within 6 weeks of the last neoadjuvant dose, and adjuvant therapy was administered within 6 weeks after surgery as assessed by the investigator.Post-surgical adjuvant therapy phase.Treatment regimen determined by the investigator (Adebrelimab1200 mg + apatinib 250 mg for up to 13 cycles is recommended for driver gene-negative patients; adjuvant treatment with TKIs is selected by the investigator for driver gene-positive patients). | Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, Jiangsu Hengrui Medicine Co.,Ltd. | pulmonary sarcomatoid carcinoma | | | | |
NCT03868852: Efficacy and Safety of Radiotherapy Combined With Apatinib Mesylate in the Treatment of Rhabdomyosarcoma in Children |
|
|
| Unknown status | 1/2 | 48 | RoW | Apatinib mesylate tablets, Three-dimensional conformal intensity modulation, 3D-IMRT | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Childhood Rhabdomyosarcoma | 04/20 | 04/20 | | |
ChiCTR2100049548: Open phase I / IIA trial of vg161 monotherapy or combined with apatinib in the treatment of advanced osteosarcoma, Ewing's sarcoma, chordoma and chondrosarcoma |
|
|
| Not yet recruiting | 1/2 | 32 | | VG161 ;VG161+apatinib | Shanghai Changzheng Hospital; Shanghai Changzheng Hospital, No | Advanced osteosarcoma, Ewing's sarcoma, chordoma and chondrosarcoma | | | | |
